Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective

Detalhes bibliográficos
Autor(a) principal: Nunes,Renata Portella
Data de Publicação: 2020
Outros Autores: Hirai,Flávio Eduardo, Rodrigues,Eduardo Buchelle, Farah,Michel Eid
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos brasileiros de oftalmologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010
Resumo: ABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.
id CBO-2_e391c9c26fb9cb19433110ef4db07f12
oai_identifier_str oai:scielo:S0004-27492020000100010
network_acronym_str CBO-2
network_name_str Arquivos brasileiros de oftalmologia (Online)
repository_id_str
spelling Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspectiveAge-related macular degenerationCost-benefit analysisRetinaBevacizumabRanibizumabABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.Conselho Brasileiro de Oftalmologia2020-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010Arquivos Brasileiros de Oftalmologia v.83 n.1 2020reponame:Arquivos brasileiros de oftalmologia (Online)instname:Conselho Brasileiro de Oftalmologia (CBO)instacron:CBO10.5935/0004-2749.20200020info:eu-repo/semantics/openAccessNunes,Renata PortellaHirai,Flávio EduardoRodrigues,Eduardo BuchelleFarah,Michel Eideng2020-02-21T00:00:00Zoai:scielo:S0004-27492020000100010Revistahttp://aboonline.org.br/https://old.scielo.br/oai/scielo-oai.phpaboonline@cbo.com.br||abo@cbo.com.br1678-29250004-2749opendoar:2020-02-21T00:00Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)false
dc.title.none.fl_str_mv Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
title Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
spellingShingle Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
Nunes,Renata Portella
Age-related macular degeneration
Cost-benefit analysis
Retina
Bevacizumab
Ranibizumab
title_short Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
title_full Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
title_fullStr Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
title_full_unstemmed Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
title_sort Cost-effectiveness of Anti-VEGF treatments for age-related macular degeneration: a Brazilian perspective
author Nunes,Renata Portella
author_facet Nunes,Renata Portella
Hirai,Flávio Eduardo
Rodrigues,Eduardo Buchelle
Farah,Michel Eid
author_role author
author2 Hirai,Flávio Eduardo
Rodrigues,Eduardo Buchelle
Farah,Michel Eid
author2_role author
author
author
dc.contributor.author.fl_str_mv Nunes,Renata Portella
Hirai,Flávio Eduardo
Rodrigues,Eduardo Buchelle
Farah,Michel Eid
dc.subject.por.fl_str_mv Age-related macular degeneration
Cost-benefit analysis
Retina
Bevacizumab
Ranibizumab
topic Age-related macular degeneration
Cost-benefit analysis
Retina
Bevacizumab
Ranibizumab
description ABSTRACT Purpose: To study the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration. Methods: We used a decision tree model to analyze the cost-effectiveness of ranibizumab and bevacizumab for the treatment of age-related macular degeneration, from the Brazilian Public Health System (SUS) perspective. Ranibizumab and bevacizumab were administered to patients with the same treatment procedure, and the difference in treatment costs was calculated based on the cost of the drugs. Direct costs were estimated using the information provided by the Brazilian SUS. Effectiveness in terms of quality-adjusted life years (QALYs) was calculated based on the utility values for visual impairment. Incremental cost-effectiveness ratio was calculated by comparing both treatments. The analytical horizon was one year. Results: The decision tree analysis showed that the difference in treatment effectiveness was 0.01 QALY. Incremental cost-effectiveness ratio showed that ranibizumab treatment required an incremental annual cost of more than R$ 2 million to generate 1 additional QALY, as compared to bevacizumab. Conclusions: From the Brazilian SUS perspective, bevacizumab is more cost-effective than ranibizumab for the treatment of neovascular age-related macular degeneration. Its use could allow potential annual savings in health budget.
publishDate 2020
dc.date.none.fl_str_mv 2020-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492020000100010
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/0004-2749.20200020
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
publisher.none.fl_str_mv Conselho Brasileiro de Oftalmologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Oftalmologia v.83 n.1 2020
reponame:Arquivos brasileiros de oftalmologia (Online)
instname:Conselho Brasileiro de Oftalmologia (CBO)
instacron:CBO
instname_str Conselho Brasileiro de Oftalmologia (CBO)
instacron_str CBO
institution CBO
reponame_str Arquivos brasileiros de oftalmologia (Online)
collection Arquivos brasileiros de oftalmologia (Online)
repository.name.fl_str_mv Arquivos brasileiros de oftalmologia (Online) - Conselho Brasileiro de Oftalmologia (CBO)
repository.mail.fl_str_mv aboonline@cbo.com.br||abo@cbo.com.br
_version_ 1754209030462504960